Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
AnaptysBio Inc(ANAB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANAB
11/10/2026: ANAB (4-star) is currently NOT-A-BUY. Pass it for now.
AnaptysBio is a clinical-stage biotechnology company that leverages its proprietary antibody discovery platform to develop novel therapeutics for inflammatory diseases. The company is known for its focus on high-affinity antibody candidates like Rosnilimab. While it has successfully validated its technology through past partnerships, it remains without commercial revenue, making its growth story entirely dependent on successful clinical trial outcomes. Investors face significant risks, including binary clinical results and intense competition from large, well-capitalized pharmaceutical entities. The stock is best suited for growth-oriented investors with high risk tolerance who are looking for exposure to potential breakthroughs in immunology and who can monitor critical development milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential for exponential growth if clinical trials succeed, but high risk of failure exists. |
| Momentum investor | Mixed fit | The stock often reacts strongly to clinical data news, creating short-term momentum opportunities. |
| Value investor | Weak fit | Valuation is difficult to justify based on traditional metrics since there are no consistent earnings or cash flows. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on reinvestment into R&D. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks are inherently volatile and unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to binary clinical trial results. |
| Valuation risk | High | The lack of commercial products makes standard valuation multiples difficult to apply. |
| Competition risk (Large Pharma) | High | Competition from firms like AbbVie and Regeneron can overwhelm smaller biotech developers. |
| Business quality | Medium | While the platform technology is well-regarded, the business model relies heavily on successful drug development. |
| Dividend income | Low / none | This is a growth-oriented biotech that does not provide income. |
| Execution risk | High | Development delays or clinical trial failures can materially impact the company's prospects. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 77.41% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.43B USD | Price to earnings Ratio - | 1Y Target Price 87.25 |
Price to earnings Ratio - | 1Y Target Price 87.25 | ||
Volume (30-day avg) 491.1K shares | Beta 0.37 | 52 Weeks Range 21.93 - 72.36 | Updated Date 11/10/2026 |
52 Weeks Range 21.93 - 72.36 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Upfront payments, milestone payments, and royalties from partners. | Revenue comes mainly from partner agreements, which can be inconsistent. |
Earnings Date
Report Date 2026-11-10 | When - | Estimate 0.41 | Actual - |
Profitability
Profit Margin 246.96% | Operating Margin (TTM) 53.38% |
Management Effectiveness
Return on Assets (TTM) 6.78% | Return on Equity (TTM) -114.55% |
Valuation
Trailing PE - | Forward PE 19.19 | Enterprise Value 1.24B | Price to Sales(TTM) 13.52 |
Enterprise Value 1.24B | Price to Sales(TTM) 13.52 | ||
Enterprise Value to Revenue 5.33 | Enterprise Value to EBITDA 21.17 | Shares Outstanding 29.90M | Shares Floating 20.50M |
Shares Outstanding 29.90M | Shares Floating 20.50M | ||
Percent Insiders 5.63 | Percent Institutions 105.88 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.